SEARCH

SEARCH BY CITATION

References

  • 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:17331745.MEDLINE
  • 2
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661.MEDLINE
  • 3
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:84958499.MEDLINE
  • 4
    Lai CL, Liaw YF, Leung NWY, Deslauriers M, Barnard J, Sanathanan L, Gray DF, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters [Abstract]. Hepatology 1997; 26(Suppl4):259A.
  • 5
    Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, Ng KY, et al. Lamivudine (100 mg od) for 1 year significantly improves necro-inflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection. [Abstract]. Hepatology 1997;26(Suppl 4):357A.
  • 6
    Tanikawa K, Hayashi N, Ichida F, Lino S, Kumada H, Ogawa N, Okida K, et al. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [Abstract]. Hepatology 1997; 26(Suppl4):259A.
  • 7
    Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3:211215.MEDLINE
  • 8
    Gilson RJ, Chopra K, Murray-Lyon IM, Newell AM, Nelson MR, Tedder RS, Toole JJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. Hepatology 1996; 24(Suppl4):281A.
  • 9
    Jeffers L, Heathcote E, Wright T, Carithers R, di Bisceglie A, Perrillo R, Rustgi V, et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection [Abstract] Antiviral Res 1998; 37:A197.
  • 10
    Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D. A preliminary study of lobucavir for chronic hepatitis B [Abstract]. Hepatology 1997; 26(Suppl4):428A.
  • 11
    Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41:14441448.MEDLINE
  • 12
    De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994; 13:12711295.
  • 13
    De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8:261272.MEDLINE
  • 14
    De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464467.MEDLINE
  • 15
    Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holly A, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32:10251030.MEDLINE
  • 16
    Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 1997; 26:13931395.MEDLINE
  • 17
    Bartholomew MM, Jansen RW, Jeffers LJ, Rajender Reddy K, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 18
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dushheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713.MEDLINE
  • 19
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717.MEDLINE
  • 20
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:12121215.MEDLINE
  • 21
    Allen MI, Deslauriers M, Andrews CW, Baldanti F, Tipples GA, Walters KA, Tyrrell DLJ, et al. Identification and biologic characterization of mutations in HBV resistant to lamivudine [Abstract]. Hepatology 1997; 26(Suppl4):430A.
  • 22
    Poch O, Sauvagat I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8:38673874.MEDLINE
  • 23
    Keulen W, Back NK, van Wijk A, Boucer CA, Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997; 71:33463350.MEDLINE
  • 24
    Quan Y, Gu Z, Li X, Li Z, Morrow CD, Wainberg MA. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 1996; 70:56425645.MEDLINE
  • 25
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993; 90:56535656.MEDLINE
  • 26
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:11481153.MEDLINE
  • 27
    Tillman HL, Trautwein C, Kruger M, Boker K, Schlitt HJ, Condreay L, Deslauriars M, et al. Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation. J Hepatol 26(Supp 1):153.
  • 28
    Tomic M, Sunjevaric I, Savtchenko ES, Blumenberg M. A rapid and simple method for introducing specific mutations into any position of DNA leaving all other positions unaltered. Nucleic Acid Res 1990; 18:16561659.MEDLINE
  • 29
    Lanford RE, Notvall L, Beams B. Nucleotide priming and reverse transcriptase activity of hepatitis B polymerase expressed in insect cells. J Virol 1995; 69:44314439.MEDLINE
  • 30
    Cleland WW. Statistical analysis of enzyme kinetic data. PurichDL, Ed. Methods in Enzymology. New York: Academic. 1979; 63:103138.
  • 31
    Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong R, Collis P, Danner SA. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:14111419.MEDLINE
  • 32
    Wainberg MA, Solomon H, Gu Z, Montaner JSG, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351357.MEDLINE
  • 33
    Cherrington JM, Mulato AS, Fuller MD, Cihlar T, Chen MS. Kinetic characterization of HIV-1 reverse transcriptases carrying mutations shown to confer decreased susceptibility to PMEA (adefovir) in vitro [Abstract] Antiviral Res 1997; 34:A59.
  • 34
    Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1995; 39:18881891.MEDLINE
  • 35
    Sarafianos SG, Das K, Ding J, Clark AD, Clark P, Boyer PL, Hughes SH, et al. Structural evidence for nucleic acid repositioning by the Met184Ile mutant of HIV-1 reverse transcriptase and implications for drug resistance [Abstract]. Antiviral Ther Q 1997; 2:8.
  • 36
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628633.MEDLINE
  • 37
    Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37:13901392.MEDLINE
  • 38
    Seifer M, Hamatake R, Bifano M, Standring DN. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J Virol 1998; 72:27652776.MEDLINE
  • 39
    Shaw T, Colledge D, Locarnini SA. Synergistic inhibition of in vitro hepadnaviral replication by PMEA and penciclovir or lamivudine [Abstract]. Antiviral Res 1997; 34:A33.